Biostem Technologies To Present At Two Upcoming Investor Conferences

(MENAFN- GlobeNewsWire - Nasdaq) POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY.

Morgan Stanley Global Healthcare Conference:

• Format: Fireside Chat
• Date: Monday, September 8, 2025
• Time: 3:20 PM ET
  

H.C. Wainwright 27 ^th Annual Global Investment Conference:

• Format: Presentation
• Date: Tuesday, September 9, 2025
• Time: 11:00 AM ET
  

Interested parties may access live and archived webcasts of the presentations on the“investors” section of the Company's website at: ir.biostemtechnologies.com .

Join BioStem's Distribution List & Social Media :
To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE , and follow us on X and LinkedIn .

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain^® processing method. BioREtain^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2TM, VENDAJE^®, VENDAJE AC^®, and VENDAJE OPTIC^®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on Twitter and LinkedIn .

Contact BioStem Technologies, Inc.:
Website:
E-Mail: ...
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail: ...
Phone: 917-497-9287

Or

Gilmartin Group
Philip Trip Taylor, Principal
E-Mail: ...
Phone: 415-937-5406

MENAFN02092025004107003653ID1110005833